Azevan Pharmaceuticals Overview
- Year Founded
-
1999
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$11.6M
- Investors
-
9
Azevan Pharmaceuticals General Information
Description
Developer of novel therapeutics designed to treat disorders of stress, mood, and behavior. The company's medicines selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of intermittent explosive disorder, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, and other affective disorders, enabling physicians to treat patients suffering from neurodegenerative diseases effectively.
Contact Information
Website
www.azevan.comCorporate Office
- 116 Research Drive
- Bethlehem, PA 18015
- United States
Corporate Office
- 116 Research Drive
- Bethlehem, PA 18015
- United States
Azevan Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 01-Jan-2019 | $11.6M | Completed | Clinical Trials - Phase 2 | ||
| 4. Grant | 01-Sep-2015 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series C) | 17-Jul-2015 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series B) | 10-Mar-2009 | $4.09M | $8.34M | Completed | Clinical Trials - Phase 2 | |
| 1. Later Stage VC (Series A) | 20-Jul-2005 | $4.25M | $4.25M | Completed | Clinical Trials - Phase 2 |
Azevan Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | 6,000,000 | $0.001000 | 8% | $1.32 | $1.32 | 1x | $1.32 | 33.86% |
| Series A | 6,500,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 36.68% |
Azevan Pharmaceuticals Comparisons
Industry
Financing
Details
Azevan Pharmaceuticals Competitors (13)
One of Azevan Pharmaceuticals’s 13 competitors is Ona Therapeutics, a Venture Capital-Backed company based in Barcelona, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ona Therapeutics | Venture Capital-Backed | Barcelona, Spain | ||||
| Avalyn Pharma | Formerly VC-backed | Boston, MA | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Volastra | Venture Capital-Backed | New York, NY |
Azevan Pharmaceuticals Patents
Azevan Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018333051-A1 | Compositions and methods for treating brain injury | Active | 15-Sep-2017 | ||
| AU-2018333051-B2 | Compositions and methods for treating brain injury | Active | 15-Sep-2017 | ||
| CA-3075759-A1 | Compositions and methods for treating brain injury | Pending | 15-Sep-2017 | ||
| EP-3681871-A1 | Compositions and methods for treating brain injury | Pending | 15-Sep-2017 | ||
| EP-3681871-A4 | Compositions and methods for treating brain injury | Pending | 15-Sep-2017 | A61K31/496 |
Azevan Pharmaceuticals Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development | Government | |||
| National Institute of Mental Health | Government | |||
| National Institutes of Neurological Disorders and Stroke | Government | |||
| AG Hill Partners | Family Office | Minority | ||
| Scientific Health Development | Venture Capital | Minority |
Azevan Pharmaceuticals FAQs
-
When was Azevan Pharmaceuticals founded?
Azevan Pharmaceuticals was founded in 1999.
-
Where is Azevan Pharmaceuticals headquartered?
Azevan Pharmaceuticals is headquartered in Bethlehem, PA.
-
What industry is Azevan Pharmaceuticals in?
Azevan Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Azevan Pharmaceuticals a private or public company?
Azevan Pharmaceuticals is a Private company.
-
What is Azevan Pharmaceuticals’s current revenue?
The current revenue for Azevan Pharmaceuticals is .
-
How much funding has Azevan Pharmaceuticals raised over time?
Azevan Pharmaceuticals has raised $10.8M.
-
Who are Azevan Pharmaceuticals’s investors?
Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Mental Health, National Institutes of Neurological Disorders and Stroke, AG Hill Partners, and Scientific Health Development are 5 of 9 investors who have invested in Azevan Pharmaceuticals.
-
Who are Azevan Pharmaceuticals’s competitors?
Ona Therapeutics, Avalyn Pharma, Cardurion, Gesynta Pharma, and Volastra are some of the 13 competitors of Azevan Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process